Costly, non-evidence based interventions for coronary artery disease

Larry Husten, on his Cardiobrief blog, reports:

Drug-eluting stents (DESs) cost Medicare an additional $1.57 billion per year, according to a study published online in the Archives of Internal Medicine.

In an editor’s note, Rita Redberg wrote that “it is time to clearly define what the value of this extraordinary investment has been in terms of patient benefits and study the harms and determine if we are getting good value for this outlay.”

In an interview on, the lead author said most of these treatments “are occurring in a population that’s not getting any survival benefit or quality-of-life benefit out of it, that is what’s troubling.”


We Welcome Comments. But please note: We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, profanity or any from anyone who doesn't list what appears to be an actual email address. We will also end any thread of repetitive comments. We don't give medical advice so we won't respond to questions asking for it. Please see more on our comments policy.

Comments are closed.